These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12678235)

  • 21. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines.
    von Hunolstein C; Gomez Miguel MJ; Pezzella C; Scopetti F; Behr-Gross ME; Halder M; Hoffmann S; Levels L; van der Gun J; Hendriksen C
    Pharmeuropa Bio; 2008 Dec; 2008(1):7-18. PubMed ID: 19220977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological methods for potency testing of tetanus toxoid vaccines for human use.
    Hendriksen C; Winsnes R
    Dev Biol (Basel); 2002; 111():131-40. PubMed ID: 12678232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The quantitative ELISA for inactivated Newcastle disease virus antigen: development of the test system and the way to a Ph. Eur in vitro potency test.
    Oei HL
    Dev Biol (Basel); 2012; 134():51-3. PubMed ID: 22888595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of alternatives to animal tests in developing countries.
    Hong HA; Hendriks J
    Dev Biol Stand; 1999; 101():209-14. PubMed ID: 10566795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use.
    Krämer B; Bruckner L; Daas A; Milne C
    Pharmeur Bio Sci Notes; 2010 Oct; 2010(2):37-55. PubMed ID: 21144488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency.
    Maas R; van Diepen M; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():313-8. PubMed ID: 12678255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release?
    Poirier B; Variot P; Delourme P; Maurin J; Morgeaux S
    Vaccine; 2010 Feb; 28(7):1796-802. PubMed ID: 20018270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines.
    Krämer B; Schildger H; Behrensdorf-Nicol HA; Hanschmann KM; Duchow K
    Biologicals; 2009 Apr; 37(2):119-26. PubMed ID: 19181541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of the European Pharmacopoeia Biological Reference Preparation (Ph. Eur. BRP) for hepatitis A vaccine type B (Aventis Pasteur) batch 2.
    Buchheit KH; Daas A
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):95-108. PubMed ID: 12448033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of a live attenuated Erysipelothrix rhusiopathiae vaccine for swine.
    Neumann EJ; Grinberg A; Bonistalli KN; Mack HJ; Lehrbach PR; Gibson N
    Vet Microbiol; 2009 Mar; 135(3-4):297-303. PubMed ID: 18977618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European regulatory framework and practices for veterinary Leptospira vaccine potency testing.
    Bruckner L
    Biologicals; 2013 Sep; 41(5):303-4. PubMed ID: 23886926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humane endpoints in the efficacy testing of swine erysipelas vaccines.
    Johannes S; Hartinger J; Hendriksen CF; Morton DB; Cussler K
    ALTEX; 2003; 20(1):11-5. PubMed ID: 12579350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral vaccination against mycoplasmal pneumonia of swine using a live Erysipelothrix rhusiopathiae vaccine strain as a vector.
    Ogawa Y; Oishi E; Muneta Y; Sano A; Hikono H; Shibahara T; Yagi Y; Shimoji Y
    Vaccine; 2009 Jul; 27(33):4543-50. PubMed ID: 19433128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful development and validation of an in vitro replacement assay for Leptospira vaccine potency tests.
    Kulpa-Eddy J
    Dev Biol (Basel); 2012; 134():101-6. PubMed ID: 22888601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.
    Pombo M; Berthold I; Gingrich E; Jaramillo M; Leef M; Sirota L; Hsu H; Arciniega J
    Biologicals; 2004 Sep; 32(3):157-63. PubMed ID: 15536047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Erysipelothrix rhusiopathiae vaccines in pigs by intradermal challenge and immune responses.
    Eamens GJ; Chin JC; Turner B; Barchia I
    Vet Microbiol; 2006 Aug; 116(1-3):138-48. PubMed ID: 16678363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Collaborative study for the establishment of a European Pharmacopoeia Biological Reference Preparation for Clostridia antiserum for serological potency testing of veterinary clostridial vaccines.
    Lucken R; Daas A; Behr-Gross ME
    Dev Biol (Basel); 2002; 111():171-80. PubMed ID: 12678238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and prevalidation of alternative methods for the potency testing of C. perfringens vaccines.
    Ebert E; Öppling V; Werner E; Cubetaler K
    ALTEX; 1998; 15(5):59-61. PubMed ID: 11178544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical evaluation of numbers of animals to be used in vaccine potency testing: a practical approach.
    Akkermans AM; Hendriksen CF
    Dev Biol Stand; 1999; 101():255-60. PubMed ID: 10566799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of batch 4 of the Biological Reference Preparation (BRP) for rabies vaccine (inactivated) for veterinary use.
    Daas A; Milne C
    Pharmeuropa Bio; 2004 Dec; 2004(1):17-22. PubMed ID: 15659282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.